CY1113204T1 - Αμιδιο της ν,ν-δις- (2-υδροξυαιθυλο) γλυκινης ως συνδετης σε προφαρμακα συζευγμενα με πολυμερη - Google Patents

Αμιδιο της ν,ν-δις- (2-υδροξυαιθυλο) γλυκινης ως συνδετης σε προφαρμακα συζευγμενα με πολυμερη

Info

Publication number
CY1113204T1
CY1113204T1 CY20121100968T CY121100968T CY1113204T1 CY 1113204 T1 CY1113204 T1 CY 1113204T1 CY 20121100968 T CY20121100968 T CY 20121100968T CY 121100968 T CY121100968 T CY 121100968T CY 1113204 T1 CY1113204 T1 CY 1113204T1
Authority
CY
Cyprus
Prior art keywords
substituted
aryls
biologically active
ligand
polymeric
Prior art date
Application number
CY20121100968T
Other languages
English (en)
Inventor
Dirk Vetter
Harald Rau
Thomas HERSEL Ulrich WEGGE
Original Assignee
Ascendis Pharma A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma A/S filed Critical Ascendis Pharma A/S
Publication of CY1113204T1 publication Critical patent/CY1113204T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)

Abstract

Περιγράφεται ένα πολυμερικό προφάρμακο που περιλαμβάνει τουλάχιστον ένα πολυμερές προσκολλημένο μέσω ενός τουλάχιστον μόνιμου δεσμού σε ένα συνδέτη μπισίνης. Ο συνδέτης μπισίνης προσκολλάται μέσω μιας προσωρινής σύνδεσης σε μια αμίνη που περιέχει βιολογικά ενεργό τμήμα. Η αμίνη που περιέχει βιολογικά ενεργή ουσία, όπως ένα φάρμακο, μπορεί να απελευθερωθεί διασπώντας την προσωρινή σύνδεση. Σε ένα παράδειγμα, το προφάρμακο ή το αντιδραστήριο συνδέτη πολυμερικού προφαρμάκου έχει την ακόλουθη δομή: (τύπος Ια) στον οποίο το Τ είναι D ή Α (με το D να είναι ένα υπόλειμμα μιας αμίνης που περιέχει βιολογικά ενεργό τμήμα και το Α να είναι μια αποχωρούσα ομάδα). To Χ είναι ένα παρεμβαλλόμενο τμήμα, όπως R13-Y1. To Υ1 είναι O, S, NR6, ηλεκτριμίδιο, μηλεϊνιμίδιο, ακόρεστοι δεσμοί άνθρακα-άνθρακα ή κάθε ετεροάτομο που περιέχει ένα ελεύθερο ζεύγος ηλεκτρονίων ή είναι απών. To R13 επιλέγεται από υποκατεστημένο ή μη υποκατεστημένο γραμμικό, διακλαδισμένο ή κυκλικό αλκύλιο ή ετεροαλκύλιο, αρύλια, υποκατεστημένα αρύλια, υποκατεστημένα ή μη υποκατεστημένα ετεροαρύλια. Τα R2 και R3 επιλέγονται ανεξάρτητα από υδρογόνο, ακυλομάδες ή προστατευτικές ομάδες για υδροξυλομάδες. Τα R4 έως R12 επιλέγονται ανεξάρτητα από υδρογόνο, X-R1, υποκατεστημένο ή μη υποκατεστημένο γραμμικό, διακλαδισμένο ή κυκλικό αλκύλιο ή ετεροαλκύλιο, αρύλια, υποκατεστημένα αρύλια, υποκατεστημένα ή μη υποκατεστημένα ετεροαρύλια, κυανό, νίτρο, αλογόνο, καρβοξυ, καρβοξαμίδιο. To R1 είναι ένα πολυμερές. Σε άλλα παραδείγματα το πολυμερές R1 τοποθετείται σε άλλες θέσεις.
CY20121100968T 2005-06-22 2012-10-17 Αμιδιο της ν,ν-δις- (2-υδροξυαιθυλο) γλυκινης ως συνδετης σε προφαρμακα συζευγμενα με πολυμερη CY1113204T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0512705A GB2427360A (en) 2005-06-22 2005-06-22 Aliphatic prodrug linker
EP06777407A EP1909845B1 (en) 2005-06-22 2006-06-21 N,n-bis-(2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs

Publications (1)

Publication Number Publication Date
CY1113204T1 true CY1113204T1 (el) 2016-04-13

Family

ID=34855956

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100968T CY1113204T1 (el) 2005-06-22 2012-10-17 Αμιδιο της ν,ν-δις- (2-υδροξυαιθυλο) γλυκινης ως συνδετης σε προφαρμακα συζευγμενα με πολυμερη

Country Status (14)

Country Link
US (1) US8980242B2 (el)
EP (1) EP1909845B1 (el)
JP (1) JP5121068B2 (el)
CN (1) CN101242859B (el)
AU (1) AU2006260914B2 (el)
BR (1) BRPI0612536A2 (el)
CA (1) CA2613208C (el)
CY (1) CY1113204T1 (el)
ES (1) ES2390816T3 (el)
GB (1) GB2427360A (el)
MX (1) MX2007016547A (el)
PL (1) PL1909845T3 (el)
SI (1) SI1909845T1 (el)
WO (1) WO2006136586A2 (el)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0615049B1 (pt) 2005-08-24 2023-04-25 Immunogen, Inc Processo para a preparação de um conjugado de anticorpo- maitansinóide
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
AU2011254001B2 (en) * 2007-01-05 2012-08-02 Covx Technologies Ireland Limited Glucagon-like protein-1 receptor (GLP-1R) agonist compounds
WO2008148839A2 (en) * 2007-06-08 2008-12-11 Ascendis Pharma As Long-acting polymeric prodrugs of exendin
EP2067494A1 (en) 2007-12-04 2009-06-10 Charité-Universitätsmedizin Berlin Sheet or tubular structure consisting of elastic biocompatible material and its use
CN101980725B (zh) 2008-02-01 2013-06-12 阿森迪斯药物股份有限公司 包含可自裂解的连接体的前药
ES2587400T3 (es) 2008-04-29 2016-10-24 Ascendis Pharma Growth Disorders Division A/S Compuestos de hormona de crecimiento humana recombinante pegilada
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
CA2742710A1 (en) 2008-11-04 2010-05-14 Janssen Pharmaceutica Nv Crhr2 peptide agonists and uses thereof
JP2012519666A (ja) 2009-03-05 2012-08-30 アセンディス ファーマ エーエス インターフェロンアルファ担体プロドラッグ
ES2904360T3 (es) 2009-05-20 2022-04-04 Biomarin Pharm Inc Variantes de péptido natriurético de tipo C
DK2437790T3 (da) 2009-06-03 2019-05-20 Immunogen Inc Konjugeringsfremgangsmåder
EP2445536B1 (en) 2009-06-22 2016-06-08 Burnham Institute for Medical Research Methods and compositions using peptides and proteins with c-terminal elements
CA2769162C (en) 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
CA2769340C (en) 2009-07-31 2018-09-11 Harald Rau Prodrugs comprising an insulin linker conjugate
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
CA2776723C (en) 2009-10-29 2018-09-25 Ascendis Pharma As Sterilization of biodegradable hydrogels
US20110105397A1 (en) 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
CN102711733A (zh) 2009-12-15 2012-10-03 阿森迪斯药物股份有限公司 瞬时连接于聚合物载体的干生长激素组合物
EP2525829A1 (en) 2010-01-22 2012-11-28 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089216A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
EP2525831B1 (en) 2010-01-22 2019-05-15 Ascendis Pharma A/S Carrier-linked carbamate prodrug linkers
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
US8795673B2 (en) 2011-03-29 2014-08-05 Immunogen, Inc. Preparation of maytansinoid antibody conjugates by a one-step process
WO2012166585A2 (en) 2011-05-31 2012-12-06 Airware, Inc. Re-calibration of ab ndir gas sensors
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
EP2741782B1 (en) 2011-08-12 2020-05-06 Ascendis Pharma A/S Protein carrier-linked prodrugs
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
CA2849192C (en) 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
CN104144705B (zh) 2011-11-03 2017-03-01 拜耳知识产权有限责任公司 用于肽的可释放性连接的基于酪氨酸的连接体
JOP20190001B1 (ar) 2011-11-03 2022-03-14 Bayer Pharma AG عقار أولي معتمد على جليكول عديد إثيلين من أدرينومدالين واستخدامه
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
CA2886228A1 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
CN105209592A (zh) 2012-10-04 2015-12-30 伊缪诺金公司 使用pvdf膜纯化细胞结合剂细胞毒性剂缀合物
AU2013328785B2 (en) 2012-10-11 2016-07-21 Ascendis Pharma A/S Hydrogel prodrugs
BR112015007778B1 (pt) 2012-10-11 2023-04-25 Ascendis Pharma Ophthalmology Division A/S Composição farmacêutica de profármacos neutralizantes de vegf ligados ao veículo para tratamento de condições oculares
MX363462B (es) 2012-10-11 2019-03-25 Ascendis Pharma As Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
US11116849B2 (en) 2013-04-22 2021-09-14 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing tagged drugs
WO2015052155A1 (en) 2013-10-08 2015-04-16 Ascendis Pharma A/S Protecting group comprising a purification tag
AU2014345511A1 (en) 2013-11-11 2016-05-12 Ascendis Pharma A/S Relaxin prodrugs
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
AU2015299055C1 (en) 2014-08-06 2021-05-06 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
AU2015323769A1 (en) 2014-09-26 2017-04-13 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
WO2016077083A1 (en) 2014-11-05 2016-05-19 University Of The Sciences In Philadelphia A high molecular weight biodegradable gelatin-doxorubicin conjugate
EP3220892B1 (en) 2014-11-21 2021-10-13 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms
EP3303365A4 (en) 2015-05-29 2019-04-24 Ascendis Pharma Inc. PRODRUGS WITH A PYROGLUTAMATE LINKER
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
WO2017118700A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with increased nep stability
BR112018011008A2 (pt) 2016-01-08 2018-12-04 Ascendis Pharma Growth Disorders As agonistas de cnp de liberação controlada com ligação a npr-c baixa
EP3400022A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
EP3400019B1 (en) 2016-01-08 2022-09-28 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
JP7059195B2 (ja) 2016-03-01 2022-04-25 アセンディス ファーマ ボーン ディジージズ エー/エス Pthプロドラッグ
SG11201807832VA (en) 2016-03-16 2018-10-30 Prolynx Llc Extended release conjugates of exenatide analogs
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JP7096813B2 (ja) 2016-08-26 2022-07-06 エクシーバ ゲーエムベーハー 組成物及びその方法
KR20240013849A (ko) 2016-09-29 2024-01-30 아센디스 파마 본 디지즈 에이/에스 조절 방출 pth 화합물을 위한 투여 용법
KR20230170810A (ko) 2016-09-29 2023-12-19 아센디스 파마 본 디지즈 에이/에스 낮은 피크 대 트로프 비를 가진 pth 화합물
KR102531327B1 (ko) 2016-09-29 2023-05-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 조절 방출 cnp 아고니스트를 사용한 병용 요법
WO2018060311A1 (en) 2016-09-29 2018-04-05 Ascendis Pharma Bone Diseases A/S Incremental dose finding in controlled-release pth compounds
AU2018240375C1 (en) 2017-03-22 2024-02-01 Ascendis Pharma A/S Hydrogel cross-linked hyaluronic acid prodrug compositions and methods
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
CN111615405B (zh) * 2017-11-17 2023-11-28 国家科学研究中心 聚合物前药及其皮下和/或肌内给药
SG11202010387QA (en) 2018-05-18 2020-11-27 Ascendis Pharma Bone Diseases As Starting dose of pth conjugates
EP3856257A1 (en) 2018-09-26 2021-08-04 Ascendis Pharma A/S Degradable hyaluronic acid hydrogels
CA3114056A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
WO2020064846A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Novel hydrogel conjugates
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣3多肽之持續遞送
WO2020141225A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
TW202042844A (zh) 2019-01-04 2020-12-01 丹麥商阿仙帝斯製藥公司 模式辨別受體(pattern recognition receptor)促效劑的共軛物
EP3906018A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
KR20210113272A (ko) 2019-01-04 2021-09-15 아센디스 파마 온콜로지 디비전 에이/에스 선천 면역 작용제를 위한 지속되는 국소 약물 수준
JP2022520193A (ja) 2019-02-11 2022-03-29 アセンディス ファーマ グロース ディスオーダーズ エー/エス Cnpコンジュゲートの乾燥医薬製剤
CN113423383A (zh) 2019-02-11 2021-09-21 阿森迪斯药物骨疾病股份有限公司 Pth缀合物的液体药物制剂
JP2022537369A (ja) 2019-06-18 2022-08-25 バイエル アクチェンゲゼルシャフト 長期安定化のためのアドレノメデュリン-類似体およびその使用
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
TW202114738A (zh) 2019-06-21 2021-04-16 丹麥商阿仙帝斯製藥公司 抗ctla4結合物
AU2020295724A1 (en) 2019-06-21 2021-12-02 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
EP4065187A1 (en) * 2019-11-30 2022-10-05 Smart Reactors Service Limited Coating for medical devices
JP2023510790A (ja) 2020-01-13 2023-03-15 アセンディス ファーマ ボーン ディジージズ エー/エス 副甲状腺機能低下症の治療
US20230241217A1 (en) 2020-05-04 2023-08-03 Ascendis Pharma A/S Hydrogel irradiation
AU2021349316A1 (en) 2020-09-28 2023-04-27 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
CN112251484B (zh) * 2020-10-26 2022-05-24 江南大学 一种脂肪酶催化制备甘氨酸寡肽-聚乙二醇共聚物的方法
CA3230895A1 (en) 2021-09-22 2023-03-30 Kennett Sprogoe Long-acting pth compound treatments
AU2022409306A1 (en) 2021-12-13 2024-06-06 Ascendis Pharma Oncology Division A/S Cancer treatments with tlr7/8 agonists
AU2022413318A1 (en) 2021-12-13 2024-05-16 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds
WO2024094673A1 (en) 2022-11-02 2024-05-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
CN117959250A (zh) * 2024-03-27 2024-05-03 长春生物制品研究所有限责任公司 一种重组人白细胞介素-1受体拮抗剂注射液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2312975C (en) 1997-12-17 2012-08-21 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
JP2005538035A (ja) * 2001-12-11 2005-12-15 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ グアニジニウム輸送試薬および結合体
US20060099660A1 (en) * 2002-02-15 2006-05-11 Synovo Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7413738B2 (en) * 2002-08-13 2008-08-19 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on biodegradable linkers
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
AU2003282624A1 (en) 2002-11-14 2004-06-03 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
EP1828399A2 (en) * 2004-12-14 2007-09-05 Enzon Pharmaceuticals, Inc. Polymer-linked pseudomonas exotoxin immunotoxin

Also Published As

Publication number Publication date
BRPI0612536A2 (pt) 2010-11-23
EP1909845B1 (en) 2012-08-15
CA2613208C (en) 2014-01-21
AU2006260914B2 (en) 2011-04-14
US8980242B2 (en) 2015-03-17
AU2006260914A1 (en) 2006-12-28
WO2006136586A3 (en) 2007-07-26
WO2006136586A2 (en) 2006-12-28
MX2007016547A (es) 2008-02-21
US20100291021A1 (en) 2010-11-18
GB2427360A (en) 2006-12-27
CA2613208A1 (en) 2006-12-28
PL1909845T3 (pl) 2013-01-31
CN101242859A (zh) 2008-08-13
GB0512705D0 (en) 2005-07-27
SI1909845T1 (sl) 2012-11-30
JP5121068B2 (ja) 2013-01-16
JP2008543916A (ja) 2008-12-04
ES2390816T3 (es) 2012-11-16
CN101242859B (zh) 2013-04-03
EP1909845A2 (en) 2008-04-16

Similar Documents

Publication Publication Date Title
CY1113204T1 (el) Αμιδιο της ν,ν-δις- (2-υδροξυαιθυλο) γλυκινης ως συνδετης σε προφαρμακα συζευγμενα με πολυμερη
AR110853A2 (es) Un método para preparar el conjugado de péptido insulinotrópico, y una composición farmacéutica que comprende a dicho conjugado de péptido insulinotrópico
ES2560003T3 (es) Inhibidores de la serina proteasa de VHC derivados de prolina macrocíclica
CY1115696T1 (el) Μεθοδος για την παρασκευη υποκατεστημενου με διαρυλιο 4-αμινο-βουτυρικου οξεος ή παραγωγων του και η χρηση τους για την παρασκευη αναστολεων νερ
AR083070A1 (es) Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc
CY1118658T1 (el) Συνθεση 18f-ραδιοεπισημασμενων στυρυλοπυριδινων απο τοσυλικες προδρομες ενωσεις και σταθερες φαρμακευτικες συνθεσεις αυτων
NO20064200L (no) Fremgangsmate for syntese av en CXCR4-antagonist
AR106944A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
CY1117990T1 (el) Μορφες 5-αζακιτιδινης
CY1111827T1 (el) Μεθοδος βιομηχανικης κατασκευης εμβολιων
CY1118650T1 (el) Παραγωγα βενζιμιδαζολιου
TR201907573T4 (tr) Konjugasyon yöntemleri̇
PE20120582A1 (es) Conjugados de insulina cristalina
BRPI0913457A2 (pt) "composto, composição farmacêutica, e, uso do composto"
AR031251A1 (es) Derivado de pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento y proceso de preparacion
PE20091575A1 (es) Derivados bifenilo como inhibidores del virus de la hepatitis c
CY1114504T1 (el) Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης
MX344330B (es) Imidazoquinolinas substituidas novedosas.
MX2010003156A (es) Derivados de aril amida substituida con tetrazol y usos de los mismos.
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1111528T1 (el) 1-αζα-δικυκλο [3.3.1] εννεανια
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
TW200640918A (en) Isoxazoline derivative and novel process for its preparation
CY1116208T1 (el) Υδατο-διαλυτη ενωση βενζοαζεπινης και η φαρμακευτικη συνθεση αυτης
UY29366A1 (es) Derivados de la n-(4,5-difenil-2-tienil)metilamina, su preparacion y su aplicación en terapéutica